Drug Discovery Weekly — 2026-05-19

FDA & Regulatory Decisions

Daraxonrasib (Revolution Medicines) — Expanded Access Authorization

• Indication: Previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)
• Significance: Pancreatic cancer remains one of the deadliest malignancies with very limited treatment options after first-line therapy. The FDA's authorization of expanded access for daraxonrasib — a RAS inhibitor — signals the agency's recognition of unmet need and meaningful clinical activity in this indication. RAS mutations are present in over 90% of pancreatic cancers, making this target class highly relevant.
• Timeline: Compassionate use program now open; formal regulatory filing timeline not yet disclosed. Pivotal trial data will determine NDA submission timing.

Ebvallo (Pierre Fabre / Atara Biotherapeutics) — CRL Reconsideration

• Indication: Rare EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD)
• Significance: After an unexpected Complete Response Letter (CRL), Pierre Fabre and Atara met with FDA officials in late April. The agency has now agreed that the companies' already-completed, single-arm clinical trial may be sufficient to support approval — a meaningful development given the FDA's broader movement toward single-study approvals. EBV+ PTLD is a rare, life-threatening complication of organ transplantation with limited treatment options.
• Timeline: The companies are working with FDA on a resubmission pathway following the productive April meeting.

3 sources

statnews.com

statnews.com

statnews.com

FDA to lower number of trials required for approval of drugs, other medical products

statnews.com

FDA to reconsider rare cancer drug Ebvallo after surprise rejection | STAT

Multiple Agents — PDUFA Dates Expected in June 2026

• Indication: Pipeline includes treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease
• Significance: June is shaping up as a heavy regulatory month across multiple therapeutic areas. The breadth of indications — from infectious disease to metabolic disorders to ophthalmology — reflects the diversified drug development pipeline entering late-stage review.
• Timeline: PDUFA action dates expected throughout June 2026.

Alecensa (Roche) — Japan Label Expansion

• Indication: All ALK-positive tumor types (expanded from prior approved indications)
• Significance: Roche's ALK inhibitor Alecensa (alectinib) gains a broader tissue-agnostic label in Japan, reflecting a global regulatory trend toward tumor-agnostic approvals based on molecular targets rather than primary tumor site. A CD20 antibody was also recently approved for active lupus nephritis, with an SLE decision expected by December 2026.
• Timeline: Japan approval granted; U.S. and EU label expansion status not disclosed in current filings.

Clinical Trial Milestones

Daraxonrasib — Phase 2/3 for Metastatic Pancreatic Ductal Adenocarcinoma

• Sponsor: Revolution Medicines
• Results: The FDA's expanded access authorization reflects sufficient clinical signal from ongoing trials to justify compassionate use. Daraxonrasib targets RAS — long considered undruggable — representing a new class of direct RAS inhibitors following the breakthrough of KRAS G12C inhibitors in lung and colorectal cancer.
• What's Next: Pivotal trial data readout expected to define the NDA filing timeline. The expanded access program provides additional real-world safety and efficacy data.

Vertex Pharmaceuticals — Phase 3 Interim Check for IgA Nephropathy Candidate

• Sponsor: Vertex Pharmaceuticals
• Results: Per earlier reporting, an interim check of Vertex's Phase 3 study could herald an accelerated approval filing in the first half of 2026. Vertex has claimed "best-in-class potential" for its dual-targeting mechanism, pointing to possible efficacy and dosing advantages over approved competitor Otsuka's therapy and Vera Therapeutics' submitted drug.
• What's Next: Accelerated approval filing expected in H1 2026 if interim data supports it.

Arrowhead Pharmaceuticals — Redemplo Phase 3 for Severe Hypertriglyceridemia

• Sponsor: Arrowhead Pharmaceuticals
• Results: Results from the Phase 3 program expected around mid-2026. If positive, an approval filing would follow shortly afterward.
• What's Next: Data readout expected mid-2026; NDA submission contingent on positive results. June 2026 PDUFA activity in the hypertriglyceridemia space makes this a closely watched catalyst.

Pharma Deals & M&A

• Broad Partnership: Bristol Myers Squibb + Hengrui Pharmaceuticals — $15B biobucks ($600M upfront). BMS formed a sweeping partnership with China's Hengrui, paying $600 million upfront to jointly advance 13 early-stage programs spanning both companies' pipelines. The deal taps China's rapidly scaling R&D infrastructure at a moment when global drugmakers are hunting for pipeline assets ahead of patent cliffs. The partnership reflects a broader 2026 surge in China-to-West licensing.

• Macro Trend — Licensing Surge: Biopharma licensing hits $82.7 billion in Q1 2026 while VC funding drops to $6.9 billion, highlighting a structural shift toward milestone-heavy, risk-sharing deal structures. Deal volume in 2026 is substantially outpacing 2025, with activity driven by interest in cancer and autoimmune disease assets. Eli Lilly and Gilead are leading acquirers.

• Manufacturing Partnership: LOTTE Biologics + Ottimo Pharma — LOTTE Biologics announced an expansion of its antibody manufacturing collaboration with Ottimo Pharma, strengthening the contract manufacturing infrastructure for Ottimo's pipeline biologics.

AI & Computational Drug Discovery

• Early AI-Designed Biologics Enter Clinical Evaluation: According to a review in The Medicine Maker, early AI-designed biologics — including peptide therapeutics, antibodies, and mRNA-based candidates — are entering clinical evaluation, demonstrating that computational design is moving beyond theory into practice. The piece notes that deep learning models analyzing 3D conformations, protein-ligand interactions, and dynamic molecular behavior are revealing new "druggable" spaces that conventional screening approaches miss.

• AI-Assisted Oncology Candidates Demonstrate Clinical Safety: A review published in BJC Reports (Nature) highlights that compounds identified through AI-assisted approaches in precision oncology are achieving acceptable safety profiles and measurable biological activity in early human trials — benchmarks that remain difficult to reach in oncology drug development. The paper cites AlphaFold's role in structure-informed drug design for cancer-associated targets and notes that AI-driven platforms are beginning to identify candidates outside conventional chemical boundaries that still demonstrate clinical efficacy.

Pipeline Watch: Key Upcoming Catalysts

• June 2026: Multiple PDUFA decisions — treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease all under active review.
• Mid-2026: Arrowhead Pharmaceuticals — Redemplo (severe hypertriglyceridemia) Phase 3 data readout; NDA filing to follow if positive.
• H1 2026: Vertex Pharmaceuticals — potential accelerated approval filing for IgA nephropathy candidate, pending interim Phase 3 data.
• December 2026: FDA decision expected on CD20 antibody for systemic lupus erythematosus (SLE) — recently approved for lupus nephritis, now under review for the broader SLE indication.
• Ongoing: Ebvallo (Pierre Fabre / Atara) resubmission pathway being finalized following productive April FDA meeting — watch for formal resubmission announcement.

Week in Context

The week's most consequential development may not be any single drug approval, but a confluence of trends reshaping how drugs reach patients. The FDA's expanded access authorization for daraxonrasib in pancreatic cancer underscores both the urgency of unmet medical need in that indication and the agency's willingness to move quickly when clinical signals are compelling. Simultaneously, the Ebvallo reconsideration — where FDA acknowledged a single-arm trial may suffice — reflects the practical implementation of the agency's broader policy shift toward single-study approval pathways, a change that could meaningfully accelerate timelines for rare disease drugs.

The BMS-Hengrui deal is the most vivid expression of a structural realignment in pharma's R&D geography. China's biotech ecosystem has matured rapidly: average upfront licensing values from Chinese partners jumped 230% between 2022 and 2026, and 2026 is on pace for a record year in China-to-West deal flow. BMS's $600 million upfront payment and $15 billion in potential biobucks signals that large Western pharma now views Chinese R&D pipelines not as bargain-basement sourcing but as legitimate best-in-class competition. The broader $82.7 billion in Q1 2026 licensing activity, against only $6.9 billion in VC funding, tells its own story: the industry is consolidating risk through structured partnerships rather than betting on standalone biotechs.

AI drug discovery is entering a new phase. The shift from "AI found a target" to "AI-designed molecule passed Phase 1" is now documented in peer-reviewed literature and early clinical programs. As AlphaFold-enabled structure-based design matures and deep learning models explore chemical spaces beyond traditional medicinal chemistry, the pipeline of AI-originated candidates entering human trials will grow substantially. The next 12-18 months will be critical for determining whether AI-originated drugs can clear Phase 2 efficacy bars — the milestone that will truly validate the technology's clinical promise.